Patient Derived Xenograft Market - Global Industry Analysis, Growth, Key Trends, Regional Assessment, and Forecast 2020 - 2030
Patient derived xenografts (PDX) are tumour in mouse models for cancer. The cells or tissues of patient’s tumour are implanted into mice for research purpose. Before checking on to the patient, cancer drugs can be tested on xenografts to check their performance. It can help in planning the treatment as per the previous tests and also development of new drugs if needed. There are athymic nude mice, severely compromised immune deficient mice, NOD-SCID mice and recombination activity gene 2 knockout mice for establishing PDX models. Growing research and development sector for cancer research and demand for humanised PDX models may provide opportunity for growth.
Increasing Use in Research may pave way for it as the Future of Cancer Treatment
Rapidly evolving field of personalised therapy can be the future oncological practice leading to the introduction of novel trial design in bio market therapy. Patient derived xenografts have been in high demand in translational research and cell line xenografts have been the standard for preclinical research which is able to create a microenvironment. PDX models are capable of accurately replicating tumour growth, diversity of tumour cells, and also ensures tumour progression including metastatic potential. In the research, PDX models were established of 4 of 9 of patients at diagnosis and all patients were tested at relapse. The results demonstrated that PDX can be established quickly and found to be equally as representative of the donor tumour.
PDX Models for Drug Testing in Head and Neck Squamous Cell Carcinoma
According to the research article published in doi.org, PDXs recapitulate the heterogeneity observed in the human tumours making them an ideal preclinical model system. PDX protocol determines the steps required for the generation of HNSCC-PDXs, the processing of tumour tissues and the expansion of PDX models into cohorts for drug testing. The bulk single cell suspensions of PDX are required for creating larger mouse cohorts. Access can be generated as a tumour response to candidate drugs.
PDX as an Innovative Surrogate Tumour Model for Investigation of Health Disparities in Triple Negative Breast Cancer
Utilisation of PDX models i9n preclinical studies has helped in the improvement of basic and clinical study outcomes in a variety of solid cancer types, including breast cancer. PDX models are extensively used in cancer research. These models facilitate direct translation of laboratory discoveries and findings to clinical practice. PDX models allow for testing of drugs or drug combinations before testing in actual patients. During the study of malignancies exhibiting a complex tumour heterogeneity, PDX models are very important and also PDX models helps in better understanding of TNBC biologic properties.
Lack in Accuracy and other Challenges may Lead to Restrain the Growth
In PDX research area, there is a lack of standardisation as the technique is relatively new. The lack of competent immune system in normal PDTX mice implies to these models not being accurately representing the disease progression. Moreover, it makes them less suitable for immunotherapeutic cancer vaccine research. PDTX models are not accurate for early tumourigenesis including the genetic events leading to tumour formation. Every time researchers need to start from the scratch to avoid using tumours already acquiring mutations. Additionally, it is very expensive to implant and grow patient’s tumour in several immune compromised models.
Prominent players in the sector include WuXi AppTec (China), Champions Oncology, Inc. (US), Pharmatest Services (Finland), Xentech (France), JSR Corporation (Japan), The Jackson Laboratory (US), Oncodesign (France), Explora Biolabs (US), Biocytogen (US), Shanghai w.e.f., (US), Certis Oncology Solutions (US), InnoSer (Netherlands), Aragen Life Sciences w.e.f. (US), Bioduro (US), Living Tumor Laboratory (Canada), Hera BioLabs (US), Abnova Corporation (Taiwan), Beijing IDMO Co. Ltd. (China), Shanghai ChemPartner Co., Ltd. (China), etc.
MacroGenics announced publication in molecular cancer therapeutics highlighting the development of MGC018, the investigational antibody drug conjugate targeting B7-H3 for the treatment of solid tumours. B7-H3 is a cell surface protein with limited expression on normal tissues but is over expressed on the epithelium and tumour associated vasculature in solid tumours. The manuscript reports that overexpression of this molecule has been shown to be associated with cancer disease severity, risk of recurrence and reduction in survival. MGc018 is comprised of an anti B7-H3 humanised lgG1 antibody conjugated via a cleavable linker to the pro-drug seco-DUocarmycin hydroxyBenzamide Azaindole.
In January 2021, Rvyu Therapeutics announced the expansion of their phase I study of SEL120 in patients with acute Myeloid Leukemia or high risk myelodysplastic syndrome to Poland. SEL 120 is a highly selective first in class CDK8/CDK19 inhibitor demonstrating efficacy in a number of solid tumour types in in vitro and in vivo models as well as in onco-hematological malignancies. SEL120 is effective in undifferentiated AML STAT5-positive cancers.
Apollomics, Inc. in May 2020 announced initiation of SPARTA Phase 2 Clinical Trial for c-MET Inhibitor APL-101. The APL-101 Phase ½ clinical trials is an international multicentre, open label study which evaluates the safety, pharmacokinetics, and also efficacy levels of APL-101. SPARTA evaluates non-small cell lung cancer activities with a mutation leading to MET exon 14 skipping, and also across tumour types with MET amplification or fusions.
North America is projected to gain the leading share for the PDX market owing to rising incidences of cancer in the region. In 2020, prostate, lung and colorectal cancer accounted for 43% out of total in men and women accounted for 50% of cases of breast, lung and colorectal cancer. Based on 2017 cases, the rate of new cases of cancer is 442.4 per 100,000 people. As per cancer.gov, by 2040 the number of cases are expected to rise to 29.5 million and death may grow up to 16.4 million due to different types of cancer. Thus, to minimise the number, there is a need of research and therefore, it may be the driving factor for PDX market growth.
Regarding cancer prevalence, India accounts for 50% of total cases globally and deaths caused by cancer are expected to rise by 36% by 2030. Liver and stomach cancer are more prevalent in Asia Pacific. China is one of the leading nations accounting for 24% of diagnosed cases and 30% of deaths worldwide in 2020. Lung cancer, stomach cancer, liver, gastrointestinal, etc. contribute to the most prevalent cases of cancer in China.
Europe accounts for second populated region for colorectal cancer. As per ESMO, Cancer affects men slightly more as compared to women with 54% of new cases. Among females breast cancer is the most common and prevalent accounting for approximately 355,000 women in European Union followed by colorectal, prostate and lung cancer. Also growing research activities in the field of oncology may strive for better opportunities for market during the forecast period.
By Tumour Type
By End User
Key Questions Answered
Research activities in various types of cancer cells, rising incidences of cancer diseases, etc.
The mice model due to factors such as capability in procurement, manipulation, and also as it requires minimum facility.
Champions Oncology, Inc. (US), Pharmatest Services (Finland), Xentech (France), JSR Corporation (Japan), The Jackson Laboratory (US), Oncodesign (France), Explora Biolabs (US), etc.
Basic Cancer Research, Preclinical Drug Development, Biomarker Analysis, etc.
The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach. The researchers compile the necessary information that enlightens the CXOs about the current growth opportunities in a specific market and enables them to make the most of the opportunities.
TMR Research is a leader in developing well-researched reports. The expertise of the researchers at TMR Research makes the report stand out from others. TMR Research reports help the stakeholders and CXOs make impactful decisions through a unique blend of innovation and analytical thinking. The use of innovation and analytical thinking while structuring a report assures complete and ideal information of the current status of the market to the stakeholders.
TMR Research has rich experience in developing state-of-the-art reports for a wide array of markets and sectors. The brilliance of the experts at TMR Research and their alacrity to conduct thorough research and create phenomenal reports makes TMR Research better than others.
5-Point Growth Formula
The 5-point growth formula developed by TMR Research provides an insight to the stakeholders and CXOs about the current situation in the market. The growth formula makes the report a perfect companion for the stakeholders and CXOs.
The 5-point growth formula includes the following points:
Current and Future Threats
Along with studying the opportunities necessary for growth, threats are also an important aspect to look upon for the companies and stakeholders in a specific sector. TMR Research studies every negative aspect that will hinder the growth of a specific area of business and includes it in the report. The stakeholders and CXOs will have the benefit of assessing the threat and take the necessary steps to prevent the hindrance caused due to the threats.
Accurate Trend Analysis
Keeping up with the latest trends is crucial in any business or sector. While stakeholders are aware of the trends that are on the surface, TMR Researchers find trends that are deeply entrenched in the particular market or sector. The reports are constantly updated with the latest trends so that the stakeholders and CXOs can derive benefits from the trends and generate good revenues.
Demography forms an important part of the growth pattern of all the markets. Diving deep into the demographics enables maximum output from specific areas. The TMR Research team assesses every region and picks out the vital points that have a large impact on the growth of a market.
The analysts at TMR Research conduct an all-round analysis on the competitive landscape of the market. The observations recorded by the analysts are added to the reports so that every stakeholder gets a glimpse of the competitive scenario and frame their business plans according to the situation.
The COVID-19 outbreak has changed the growth projections of numerous sectors and businesses. The analysts at TMR Research have conducted a conscientious survey on the markets after the pandemic struck. The analysts have put forth their brilliant and well-researched opinions in the report. The opinions will help the stakeholders to plan their strategy accordingly.
The reports offer answers to the top 7 questions that revolve around the growth of the market
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report